Literature DB >> 17410335

Expression of human MCM6 and DNA Topo II alpha in craniopharyngiomas and its correlation with recurrence of the tumor.

Jianguo Xu1, Sizhong Zhang, Chao You, Siqing Huang, Bowen Cai, Xiaojie Wang.   

Abstract

Craniopharyngioma often recurs after resection resulting in poor outcome for the affected patients. The reliable criteria for predicting the tumor behavior are still lacking. It has been suggested that proliferative potential of the tumor cells is necessary for recurrence. Present study evaluated the cell multiplication activity, which is possibly related to relapse in 32 patients with adamantine epithelioma (AE) and 31 patients with squamous papillary tumor (SP). For this tissue specimens from their primary and recurring tumors were collected and immunohistochemical analysis of the expression of minichromosome maintenance protein 6 (MCM6) and DNA topoisomerase II alphalpha (DNA Topo II alpha) in the tumor sections was performed by quantitative microscopy. It was found that the MCM6 label index (LI) was significantly higher in AE than that of SP, and in the primary tumors of both subtypes the LIs of tumors with recurrence were higher than those without recurrence. There was a strong linear positive correlation between MCM6 LI and DNA Topo II alpha LI (r = 0.713; p = 0.000) in the craniopharyngiomas studied. The median MCM6 LI of the total 20 recurrent craniopharyngiomas (31.49%) was not significantly different from that of their primary tumors (29.65%). The long term risk of tumor recurrence is higher in AE than SP and it is associated with MCM6 and DNA Topo II alpha expression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17410335     DOI: 10.1007/s11060-006-9284-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.506


  42 in total

1.  Ki-Mcm6, a new monoclonal antibody specific to Mcm6: comparison of the distribution profile of Mcm6 and the Ki-67 antigen.

Authors:  H J Heidebrecht; F Buck; E Endl; M L Kruse; S Adam-Klages; K Andersen; S O Frahm; C Schulte; H H Wacker; R Parwaresch
Journal:  Lab Invest       Date:  2001-08       Impact factor: 5.662

2.  MCM2-7 complexes bind chromatin in a distributed pattern surrounding the origin recognition complex in Xenopus egg extracts.

Authors:  Melissa C Edwards; Antonin V Tutter; Christin Cvetic; Catherine H Gilbert; Tatyana A Prokhorova; Johannes C Walter
Journal:  J Biol Chem       Date:  2002-06-26       Impact factor: 5.157

3.  Craniopharyngioma: early and long term recurrence after partial removal.

Authors:  A Nishimoto; T Matsuhisa; K Kunishio; T Maeshiro; T Furuta; T Ohmoto
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-01       Impact factor: 10.154

4.  Malignant transformation in craniopharyngioma.

Authors:  G A Nelson; F O Bastian; M Schlitt; R L White
Journal:  Neurosurgery       Date:  1988-02       Impact factor: 4.654

5.  Proliferative activity in craniopharyngiomas: clinicopathological correlations in adults and children.

Authors:  R Raghavan; W T Dickey; L R Margraf; C L White; C Coimbra; L S Hynan; E J Rushing
Journal:  Surg Neurol       Date:  2000-09

6.  Minichromosome maintenance proteins as biological markers of dysplasia and malignancy.

Authors:  A Freeman; L S Morris; A D Mills; K Stoeber; R A Laskey; G H Williams; N Coleman
Journal:  Clin Cancer Res       Date:  1999-08       Impact factor: 12.531

Review 7.  The WHO classification of tumors of the nervous system.

Authors:  Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

8.  Suprasellar tumors in children: a review of clinical manifestations and managements.

Authors:  D I Sung
Journal:  Cancer       Date:  1982-10-01       Impact factor: 6.860

9.  The descriptive epidemiology of craniopharyngioma.

Authors:  G R Bunin; T S Surawicz; P A Witman; S Preston-Martin; F Davis; J M Bruner
Journal:  J Neurosurg       Date:  1998-10       Impact factor: 5.115

10.  Long term results in the management of craniopharyngiomas.

Authors:  F G McMurry; R W Hardy; D F Dohn; E Sadar; W J Gardner
Journal:  Neurosurgery       Date:  1977 Nov-Dec       Impact factor: 4.654

View more
  5 in total

1.  Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype.

Authors:  Oluf Dimitri Røe; Endre Anderssen; Eli Helge; Caroline Hild Pettersen; Karina Standahl Olsen; Helmut Sandeck; Rune Haaverstad; Steinar Lundgren; Erik Larsson
Journal:  PLoS One       Date:  2009-08-07       Impact factor: 3.240

2.  The cell-cycle kinetics of craniopharyngioma and its clinical significance.

Authors:  Jianguo Xu; Chao You; Liangxue Zhou; Qiang Li; Peizhi Zhou; Ni Chen
Journal:  J Neurooncol       Date:  2009-11-24       Impact factor: 4.130

3.  High MCM6 Expression as a Potential Prognostic Marker in Clear-cell Renal Cell Carcinoma.

Authors:  Nu-Ri Jang; Jina Baek; Younghwii Ko; Phil Hyun Song; Mi-Jin Gu
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.406

4.  MCM2-7 in Clear Cell Renal Cell Carcinoma: MCM7 Promotes Tumor Cell Proliferation.

Authors:  Junneng Zhang; Huanzong Zhang; Yinghui Wang; Qingshui Wang
Journal:  Front Oncol       Date:  2021-12-21       Impact factor: 6.244

5.  Genome wide comparative comprehensive analysis of Plasmodium falciparum MCM family with human host.

Authors:  Abulaish Ansari; Renu Tuteja
Journal:  Commun Integr Biol       Date:  2012-11-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.